Xilio Therapeutics (XLO) Competitors $0.83 +0.00 (+0.29%) As of 12:27 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock XLO vs. IPHA, TARA, ELDN, ACTU, CCCC, GNLX, THTX, CTOR, ZURA, and TVGNShould you be buying Xilio Therapeutics stock or one of its competitors? The main competitors of Xilio Therapeutics include Innate Pharma (IPHA), Protara Therapeutics (TARA), Eledon Pharmaceuticals (ELDN), Actuate Therapeutics (ACTU), C4 Therapeutics (CCCC), Genelux (GNLX), Theratechnologies (THTX), Citius Oncology (CTOR), Zura Bio (ZURA), and Tevogen Bio (TVGN). These companies are all part of the "pharmaceutical products" industry. Xilio Therapeutics vs. Its Competitors Innate Pharma Protara Therapeutics Eledon Pharmaceuticals Actuate Therapeutics C4 Therapeutics Genelux Theratechnologies Citius Oncology Zura Bio Tevogen Bio Xilio Therapeutics (NASDAQ:XLO) and Innate Pharma (NASDAQ:IPHA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, media sentiment, dividends, profitability, valuation and earnings. Do analysts rate XLO or IPHA? Xilio Therapeutics presently has a consensus target price of $3.00, suggesting a potential upside of 262.76%. Innate Pharma has a consensus target price of $6.50, suggesting a potential upside of 227.29%. Given Xilio Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Xilio Therapeutics is more favorable than Innate Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Xilio Therapeutics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.75Innate Pharma 1 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has higher earnings & valuation, XLO or IPHA? Innate Pharma has lower revenue, but higher earnings than Xilio Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioXilio Therapeutics$6.34M6.76-$58.24M-$0.76-1.09Innate Pharma$6.00M30.52-$53.53MN/AN/A Does the media favor XLO or IPHA? In the previous week, Xilio Therapeutics had 1 more articles in the media than Innate Pharma. MarketBeat recorded 2 mentions for Xilio Therapeutics and 1 mentions for Innate Pharma. Xilio Therapeutics' average media sentiment score of 0.00 equaled Innate Pharma'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xilio Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Innate Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders and institutionals hold more shares of XLO or IPHA? 54.3% of Xilio Therapeutics shares are owned by institutional investors. Comparatively, 0.2% of Innate Pharma shares are owned by institutional investors. 6.3% of Xilio Therapeutics shares are owned by insiders. Comparatively, 31.9% of Innate Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has more risk & volatility, XLO or IPHA? Xilio Therapeutics has a beta of -0.07, indicating that its stock price is 107% less volatile than the S&P 500. Comparatively, Innate Pharma has a beta of 0.04, indicating that its stock price is 96% less volatile than the S&P 500. Is XLO or IPHA more profitable? Innate Pharma has a net margin of 0.00% compared to Xilio Therapeutics' net margin of -374.79%. Innate Pharma's return on equity of 0.00% beat Xilio Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Xilio Therapeutics-374.79% -399.15% -58.68% Innate Pharma N/A N/A N/A SummaryXilio Therapeutics and Innate Pharma tied by winning 7 of the 14 factors compared between the two stocks. Get Xilio Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for XLO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding XLO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XLO vs. The Competition Export to ExcelMetricXilio TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$42.86M$3.33B$6.11B$10.60BDividend YieldN/A2.29%5.51%4.67%P/E Ratio-1.0921.6985.6427.09Price / Sales6.76414.88586.65183.87Price / CashN/A46.3226.3031.10Price / Book2.079.9913.206.71Net Income-$58.24M-$52.22M$3.30B$276.23M7 Day Performance-1.86%6.33%5.17%3.76%1 Month Performance18.18%12.68%8.88%10.97%1 Year Performance3.37%25.88%88.05%40.73% Xilio Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XLOXilio Therapeutics1.6788 of 5 stars$0.83+0.3%$3.00+262.8%+5.7%$42.86M$6.34M-1.0970IPHAInnate Pharma2.7073 of 5 stars$1.82+2.0%$6.50+257.9%-7.5%$164.09M$21.77M0.00220Positive NewsGap UpTARAProtara Therapeutics1.5387 of 5 stars$4.41+3.8%$19.60+344.4%+172.1%$163.97MN/A-2.7230ELDNEledon Pharmaceuticals2.3753 of 5 stars$2.54-5.6%$10.00+293.7%+9.2%$161.08MN/A-2.1710Positive NewsGap UpACTUActuate Therapeutics1.4841 of 5 stars$6.77-1.7%$20.33+200.3%-5.9%$160.15MN/A0.0010CCCCC4 Therapeutics3.7147 of 5 stars$2.23flat$8.50+281.2%-57.6%$158.71M$35.58M-1.41150GNLXGenelux1.4777 of 5 stars$4.25+1.2%$20.33+378.4%+80.2%$158.65MN/A-4.9410Positive NewsTHTXTheratechnologiesN/A$3.42+0.9%N/A+184.3%$157.21M$84.38M-17.99140Upcoming EarningsHigh Trading VolumeCTORCitius Oncology3.3424 of 5 stars$2.03+1.5%$6.00+195.6%+57.1%$156.74MN/A0.00N/AZURAZura Bio3.1591 of 5 stars$2.99+24.1%$11.60+288.0%-4.8%$156.69MN/A-4.273High Trading VolumeTVGNTevogen Bio2.3586 of 5 stars$0.79-1.1%$10.00+1,169.7%+132.5%$156.64MN/A-4.153 Related Companies and Tools Related Companies IPHA Competitors TARA Competitors ELDN Competitors ACTU Competitors CCCC Competitors GNLX Competitors THTX Competitors CTOR Competitors ZURA Competitors TVGN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:XLO) was last updated on 10/7/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredU.S. Government Sparking Crypto RallyU.S. Puts GDP on the Blockchain Could this spark the next crypto supercycle? Discover the altcoins poised t...Crypto 101 Media | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xilio Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xilio Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
